medigraphic.com
ISSN 2225-4676 (Electronic)

2022, Number 2

<< Back Next >>

Rev Cubana Neurol Neurocir 2022; 12 (2)

Current treatment proposal for children and adolescents in status epilepticus in Cuba

Luis LC, García GRJ

Language: Spanish
References: 22
Page: 1-16
PDF size: 509.45 Kb.


ABSTRACT

Introduction: The adequate treatment of status epilepticus depends on many factors; among these, the availability of medicines, the experience of who indicates it, who, and where it is applied.
Objective: To propose a treatment protocol for children and adolescents in status epilepticus, not including status without motor manifestations or in newborns, which is currently feasible in Cuba. Acquisition of the evidence: The search was carried out in the available databases in Google and PubMed/Medline. Articles in English and Spanish published in the last ten years and others referenced in the reviewed literature were included. Some related to care for adults and children were included due to their importance, but they clarify the position of the authors in both groups.
Results: They are based on the published reports and the experience acquired in the Pediatric Neurology Service, in the Emergency Department and in the Pediatric Intensive Care Unit at Juan Manuel Márquez Pediatric Teaching Hospital, since 1990; to try to reduce the time of epileptic activity and thus reduce the risk of mortality, morbidity and improve the quality of life of patients. The use of benzodiazepines was the first recommended treatment option, followed by a second dose, or by IV phenytoin, or the combination, in case of non-control.
Conclusions: The use of benzodiazepines (diazepam or midazolam) and IV phenytoin are the drugs of choice in early and established status epilepticus. Next, the administration of other drugs is less well defined. Rectal sodium valproate and enteral topiramate, in status epilepticus, can be considered in Cuba, although they are not included among the most internationally recommended drugs.


REFERENCES

  1. García Morales I, Fernández Alonso C, Behzadi Koochani N, Serratosa Fernández JM, Gil-Nagel Rein A, Toledo M, et al. Documento de consenso para el tratamiento del paciente con crisis epiléptica urgente. Emergencias. 2020 [acceso 08/02/2022];32:353-62. Disponible en: https://www.samfyc.es/wp-content/uploads/2021/04/Emergencias-2020_32_5_353-362-362.pdf

  2. Ferro MA, Chin RFM, Camfield CS, Wiebe S, Levin SD, Speechley KN, et al. Convulsive status epilepticus andhealth-related quality of life in childrenwith epilepsy. Neurology. 2014;83:752-7. DOI: 10.1212/WNL.0000000000000710

  3. Santos Santos A, Morales Chacón LM, Dearriba Romanidy MU. Actualización sobre la etiología de la epilepsia. Rev Cubana Neurol Neurocir. 2019 [acceso 06/02/2022];9(2):e312. Disponible en: http://www.revneuro.sld.cu/index.php/neu/article/view/312/564

  4. Mercadé Cerdá JM, Toledo Argani M, Mauri Llerda JA, López Gonzalez FJ, Salas Puig X, Sancho Rieger J, et al. The Spanish Neurological Society official clinical practice guidelines in epilepsy. Neurología. 2016;31:121-9. DOI: 10.1016/j.nrl.2013.12.020

  5. González Hermosa A. Estatus epiléptico. Protoc diagn terpediatr. 2020;119-40.

  6. Espinoza Díaz C, Cárdenas Bueno A, Vázquez Zeas M, García Klinger L, Toscano Núñez AH, García Alvarado L, et al. Estatus epiléptico en niños: aspectos generales diagnósticos y terapéuticos. AVFT. 2019 [acceso 08/02/2022];38(3):377-81. Disponible en: https://www.revistaavft.com/images/revistas/2019/avft_3_2019/22_estatus_epileptic_ni%C3%B1os.pdf

  7. Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus. Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515-23. DOI: doi.org/10.1111/epi.13121

  8. Trinkaa E, Kälviäinen R. 25 years of advances in the definition, classification and treatment of status epilepticus. Seizure. 2017;44:65-73. DOI: doi.org/10.1016/j.seizure.2016.11.001

  9. Belen Viaggio M, Bernater RD, Campanille V, Fontela ME. Status epiléptico: consideraciones clínicas y guías terapéuticas. Revista Neurológica Argentina. 2007 [acceso 08/02/2022];32:56-62. Disponible en: https://www.imbiomed.com.mx/articulo.php?id=46130

  10. Glauser T, Shinnar S, Gloss D, Alldredge B, Pharm D, Arya R, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Currents. 2016;16 (1):48-61. DOI: 10.5698/1535-7597-16.1.48.

  11. Vergara JP, Ladino L, Castro CA, Gómez B, Forero E, Vargas J, et al. Tratamiento del estado epiléptico, consenso de expertos. Asociación Colombiana de Neurología, Comité de Epilepsia Acta Neurol Colomb. 2019;35(2):74-88. DOI: doi.org/10.22379/24224022237

  12. Vasquez A, Gaınza-Lein M, Abend NS, Amengual-Gual M, Anderson A, Arya R, et al. First-line medication dosing in pediatricrefractory status epilepticus. Neurology. 2020;95:e2683-e2696. DOI:10.1212/WNL.0000000000010828

  13. Kima D, Kima JM, Won Chob Y, Ik Yangc K, Wook Kimd D, Lee ST, et al. Antiepileptic Drug Therapy for Status Epilepticus. J Clin Neurol. 2021;17(1):11-9. DOI: doi.org/10.3988/jcn.2021.17.1.11

  14. Samanta D, Garrity L, Arya R. Refractory and Super-refractory Status Epilepticus. Indian pediatrics. 2020;57:239-53. DOI: 10.1007/s13312-020-1759-0

  15. Marawar R, Basha M, Mahulikar A, Desai A, Suchdev K, Shah A, et al. Updates in Refractory Status Epilepticus. Critical Care Research and Practice. 2018:19. DOI: doi.org/10.1155/2018/9768949

  16. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinicaltreatment protocol. Brain. 2011;134:2802-18. DOI: 10.1093/brain/awr215

  17. McKenzie KC, Hahn CD, Friedman JN. Emergency management of the paediatric patient with convulsive status epilepticus. Paediatrics & Child Health. 2021:50-7. DOI: 10.1093/pch/pxaa127

  18. Rai1 S, Drislane FW. Treatment of Refractory and Super-refractory Status Epilepticus. Neurotherapeutics. 2018;15:697-712. DOI: doi.org/10.1007/s13311-018-0640-5

  19. DeLorenzo RJ, Waterhouse EJ, Towne AR, Boggs JG, Ko D, DeLorenzo GA, et al. Persistent nonconvulsivestatus epilepticus after the control of convulsive status epilepticus. Epilepsia. 1998;39:833-40. DOI: 10.1111/j.1528-1157.1998.tb01177.x.

  20. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overviewof the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000 [acceso 16/02/2022];41(suppl1):S3-89. Disponible en: https://pubmed.ncbi.nlm.nih.gov/10768292/

  21. Towne AR, Garnett LK, Waterhouse EJ, Morton LD, De Lorenzo RJ. The use of topiramate in refractory status epilepticus. Neurology. 2003;60:332-4. DOI: 10.1212/01.wnl.0000042783.86439.27.

  22. Ferlisi M, Shorvon S. The outcome of therapies in refractory andsuper-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135(Pt 8):2314-28. DOI: 10.1093/brain/aws091.




2020     |     www.medigraphic.com